NextCell Pharma

NextCell Pharma is a Swedish biotechnology company based in Huddinge that develops cell therapies and advanced therapy medicinal products (ATMPs) built on mesenchymal stromal cells. Its business combines a clinical-stage drug development platform with two commercial activities: Cellaviva, a stem cell banking service, and QVance, an analysis service for advanced therapies.

— NextCell Pharma
%
Cell therapy development20% Clinical-stage mesenchymal stromal cell therapies, including the NXTCL/ProTrans program.
Stem cell banking65% Cellaviva’s family banking service for collection and long-term storage of newborn stem cells.
ATMP analysis services10% QVance laboratory and analysis services for developers of advanced therapies.
Research-use cell products5% Cell-based products sold for research and development use, including NextCell-Cord RUO.

NextCell sells to two main customer groups: families seeking newborn stem cell banking through Cellaviva, and life...

  • Expectant parents and familiesprimary

    Buy Cellaviva stem cell banking services to preserve newborn cells for possible future medical needs.

  • ATMP developers and biotech companiessecondary

    Use QVance analysis services to support development, characterization, and quality work for advanced therapies.

  • Research institutions and life science labssecondary

    Purchase research-use cell products such as NextCell-Cord RUO for regenerative medicine and cell biology work.

  • Clinical and licensing partnerssecondary

    Engage with the ProTrans/NXTCL platform for clinical development, validation, and potential commercialization.

NextCell is headquartered in Huddinge, Sweden, and its core commercial base is in Scandinavia, where Cellaviva is...

  • •Headquartered in Huddinge, Sweden, near Karolinska University Hospital
  • •Cellaviva serves the Scandinavian family stem cell banking market
  • •QVance targets Nordic demand for ATMP analysis services
  • •Research-use products are distributed across major global markets
  • •Clinical and partnering activity extends beyond Sweden into international networks

NextCell’s strategy is to standardize and commercialize its NXTCL cell-therapy platform while advancing the lead type 1...

01
Commercialize the type 1 diabetes programshort-term

The lead asset is the main value driver and validates the platform if approved.

02
Expand the clinical pipelinemedium-term

Additional indications can broaden the addressable market and reduce single-asset dependence.

03
Scale manufacturing and process optimizationmedium-term

Standardized production is necessary for reproducible cell therapies and future commercialization.

04
Build commercial revenue from services and productsshort-term

Cellaviva and QVance provide nearer-term revenue and customer access while the pipeline matures.

NextCell faces the typical risks of clinical-stage biotech: trial outcomes may not confirm safety or efficacy,...

critical

Clinical development failure

Early results may not translate into larger studies or approval, which could block commercialization.

Scope
ProTrans/NXTCL pipeline
Materiality
high
high

Regulatory and approval risk

ATMPs require extensive evidence and regulatory clearance before market launch.

Scope
Cell therapy programs
Materiality
high
high

Financing and dilution risk

Development and market-building activities may require additional capital raises.

Scope
Group-wide
Materiality
high
medium

Key-person dependence

The business relies on specialized scientific, clinical, and regulatory expertise.

Scope
Management and R&D organization
Materiality
medium
medium

Commercial execution risk

Cellaviva and QVance depend on customer acquisition and sustained demand in niche markets.

Scope
Service businesses
Materiality
medium
Deferred revenue from stem cell storage
Cellaviva revenue and liabilities
Clinical development expense recognition
Operating loss and cash burn
Contingent liabilities and disputes
Other liabilities and expense recognition
Valuation of strategic investments
Balance sheet and non-operating items

NextCure, Inc.

NXTC · Pharmaceutical Preparations

NEXT-ChemX Corporation.

Miscellaneous Chemical Products

Cellectar Biosciences, Inc.

CLRB · Pharmaceutical Preparations

Intellia Therapeutics, Inc.

NTLA · In Vitro & In Vivo Diagnostic Substances

CEL SCI CORP

CVM · Biological Products, (No Diagnostic Substances)

NextPlat Corp

NXPL · Telephone Communications (No Radiotelephone)

: 11/08/2026